CEO Reine Allan buys 125,000 shares at $1.18 as stock drops -84.7% from 52-week high; 2 other insiders buy simultaneously
Reine Allan, CEO of Prime Medicine, purchased 125,000 shares at $1.18 on 2025-05-21, establishing an initial position in a company generating $1.5M quarterly revenue but reporting $-51.9M net income. The stock has collapsed -84.7% from its 52-week high of $8.03 and is down -27.2% over the past 30 days, trading at $1.23 near the bottom of its annual range. This buy occurs as part of a cluster pattern where 2 other insiders also purchased shares within 14 days, suggesting coordinated accumulation at depressed absolute price levels. The timing—into steep momentum decline and against a backdrop of unprofitable operations—warrants examination of whether this reflects fundamental assessment of undervaluation or other strategic objectives driving the CEO and peer insiders simultaneously.